A2 liver transplantation across the ABO barrier: Increasing options in the donor pool?
Jin Ge, John P. Roberts, Jennifer C. Lai – 2 January 2018
Jin Ge, John P. Roberts, Jennifer C. Lai – 2 January 2018
Darrick K. Li, Raymond T. Chung – 2 January 2018
Darrick K. Li, Raymond T. Chung – 2 January 2018
Amy G. Ogurick, Nicolas M. Intagliata – 2 January 2018
Kellie Young, Robert Wong – 2 January 2018
Arash Grakoui, Christopher M. Walker – 27 December 2017
Ajay C. Donepudi, Jessica M. Ferrell, Shannon Boehme, Hueng‐Sik Choi, John Y.L. Chiang – 27 December 2017 – Alcoholic fatty liver disease (AFLD) is a major risk factor for cirrhosis‐associated liver diseases. Studies demonstrate that alcohol increases serum bile acids in humans and rodents. AFLD has been linked to cholestasis, although the physiologic relevance of increased bile acids in AFLD and the underlying mechanism of increasing the bile acid pool by alcohol feeding are still unclear.
Patrik Nasr, Simone Ignatova, Stergios Kechagias, Mattias Ekstedt – 27 December 2017 – Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease in the world. The complete natural history of NAFLD is unknown because few high‐quality follow‐up studies have been conducted. Our aim was to find variables predicting disease severity through an extended follow‐up with serial biopsies.
Nipun Verma, Pramod Kumar, Suvradeep Mitra, Sunil Taneja, Sahajal Dhooria, Ashim Das, Ajay Duseja, Radha Krishan Dhiman, Yogesh Chawla – 27 December 2017 – Idiosyncratic drug‐induced liver injury (DILI) is ranked among the top most common etiologies of acute liver failure (ALF). It carries poor transplant‐free survival. Pirfenidone is an anti‐inflammatory and antifibrotic drug that is commonly used for the treatment of idiopathic pulmonary fibrosis (IPF). Hepatotoxicity due to pirfenidone is rare and generally manifests as a mild rise in serum aminotransferases.
Mohamed Safwan, Shunji Nagai, Kelly Collins, Michael Rizzari, Atsushi Yoshida, Marwan Abouljoud – 27 December 2017 – Although minimally invasive techniques for living donor hepatectomy have been developed, the surgical feasibility and limitations remain to be elucidated. The risks and outcomes involved need to be better understood prior to their widespread application. The aim of this study was to assess feasibility of minimally invasive donor hepatectomy by reviewing our experience.